← back to search

Ang Lin

Fuzhou University · CN
Area of research
Immunology · Molecular Biology
Research interest
Research interests include Immunotherapy and Immune Responses, Immune Response and Inflammation, RNA Interference and Gene Delivery, and Immune cells in cancer.
h-index
25
citations
3,336
works
64
NIH funding
primary concept
email

Recent publications

A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression
npj Vaccines 2024cited by 37position: middledoi
Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques
Emerging Microbes & Infections 2024cited by 31position: lastdoi
Algorithm for optimized mRNA design improves stability and immunogenicity
Nature 2023cited by 425position: middledoi
Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses
Immunity 2023cited by 69position: middledoi
Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses
Nature Communications 2023cited by 48position: middledoi
Delayed generation of functional virus-specific circulating T follicular helper cells correlates with severe COVID-19
Nature Communications 2023cited by 28position: middledoi
Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity
Journal of Clinical Investigation 2021cited by 114position: middledoi
Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation
Journal for ImmunoTherapy of Cancer 2020cited by 200position: middledoi
Effects of tumour necrosis factor on cardiovascular disease and cancer: A two-sample Mendelian randomization study
EBioMedicine 2020cited by 154position: middledoi
Route of Vaccine Administration Alters Antigen Trafficking but Not Innate or Adaptive Immunity
Cell Reports 2020cited by 150position: middledoi
A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates
Science Advances 2020cited by 87position: middledoi
Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans
Journal of Clinical Investigation 2020cited by 61position: firstdoi
Circulating interleukins in relation to coronary artery disease, atrial fibrillation and ischemic stroke and its subtypes: A two-sample Mendelian randomization study
International Journal of Cardiology 2020cited by 57position: middledoi
Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates
Cancer Immunology Immunotherapy 2019cited by 234position: middledoi
Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques
Molecular Therapy 2017cited by 394position: middledoi
Neutrophils acquire the capacity for antigen presentation to memory CD4+ T cells in vitro and ex vivo
Blood 2017cited by 302position: middledoi
Granulocytes: New Members of the Antigen-Presenting Cell Family
Frontiers in Immunology 2017cited by 159position: firstdoi
Induction of Robust B Cell Responses after Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells
Frontiers in Immunology 2017cited by 138position: middledoi
Matrix Metalloproteinase Responsive Nanoparticles for Synergistic Treatment of Colorectal Cancer via Simultaneous Anti-Angiogenesis and Chemotherapy
Bioconjugate Chemistry 2016cited by 36position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Karin Loré · Karolinska University Hospital11 papers (2017–2024)Sebastian Ols · Karolinska University Hospital5 papers (2017–2023)Frank Liang · University of Gothenburg4 papers (2017–2020)Elizabeth A. Thompson · University of Pennsylvania3 papers (2017–2020)Fredrika Hellgren · Karolinska University Hospital3 papers (2017–2023)Gunilla B. Karlsson Hedestam · Science for Life Laboratory2 papers (2020–2023)Stephen Burgess · Cambridge University Health Partners2 papers (2020–2020)Susanna C. Larsson · Karolinska Institutet2 papers (2020–2020)Weijun Zhao · Xiamen University2 papers (2024–2024)Jiesen Hu · China Pharmaceutical University2 papers (2024–2024)Leilei Shi · National University of Singapore2 papers (2024–2024)Shiyu Sun · Nantong University2 papers (2024–2024)Gustaf Lindgren · Karolinska University Hospital2 papers (2017–2017)Lulu Huang · China Pharmaceutical University2 papers (2024–2024)Luis A. Brito · Moderna Therapeutics (United States)2 papers (2017–2017)Changzhen Weng · China Pharmaceutical University2 papers (2024–2024) · 2 papers (2017–2017)Giuseppe Ciaramella · Beam Therapeutics (United States)2 papers (2017–2017)Hugh Salter · Karolinska University Hospital2 papers (2017–2017)Alberto Cagigi · International Vaccine Institute2 papers (2021–2023)